Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10001782HBVENSG00000105851.11protein_codingPIK3CGYesNo5294P48736
TVIS10023515HBVENSG00000105851.11protein_codingPIK3CGYesNo5294P48736
TVIS10030913HBVENSG00000105851.11protein_codingPIK3CGYesNo5294P48736
TVIS30013925HIVENSG00000105851.11protein_codingPIK3CGYesNo5294P48736
TVIS30020890HIVENSG00000105851.11protein_codingPIK3CGYesNo5294P48736
TCGA Plot Options
Drug Information
GenePIK3CG
DrugBank IDDB11952
Drug NameDuvelisib
Target IDBE0001315
UniProt IDP48736
Regulation Typeinhibitor
PubMed IDs24244039; 28945111; 28388280
CitationsBoyle DL, Kim HR, Topolewski K, Bartok B, Firestein GS: Novel phosphoinositide 3-kinase delta,gamma inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis. J Pharmacol Exp Ther. 2014 Feb;348(2):271-80. doi: 10.1124/jpet.113.205955. Epub 2013 Nov 15.@@Lampson BL, Brown JR: PI3Kdelta-selective and PI3Kalpha/delta-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs. 2017 Nov;26(11):1267-1279. doi: 10.1080/13543784.2017.1384815. Epub 2017 Oct 6.@@Vangapandu HV, Jain N, Gandhi V: Duvelisib: a phosphoinositide-3 kinase delta/gamma inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017 May;26(5):625-632. doi: 10.1080/13543784.2017.1312338. Epub 2017 Apr 13.
GroupsApproved; Investigational
Direct ClassificationIsoquinolones and derivatives
SMILESC[C@H](NC1=C2N=CNC2=NC=N1)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1
Pathways
PharmGKB
ChEMBLCHEMBL3039502